If you got a question, look no further.
We post the most common questions
in our FAQ section.
Please fill in the form below to receive a Free Sample of the Report.
Dottikon ES Holding AG (DESN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.The profile contains critical company information including:- Business description A detailed description of the company's operations and business divisions.- Corporate strategy Analyst's summarization of the company's business strategy.- SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.- Company history Progression of key events associated with the company.- Major products and services A list of major products, services and brands of the company.- Key competitors A list of key competitors to the company.- Key employees A list of the key executives of the company.- Executive biographies A brief summary of the executives’ employment history.- Key operational heads A list of personnel heading key departments/functions.- Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.- Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.- Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.HighlightsDottikon ES Holding AG (Dottikon) manufactures and commercializes active pharmaceutical ingredients (APIs), performance chemicals and intermediates for chemical and pharmaceutical industries. The company specializes in hazardous reactions with focus on exothermal reactions, highly reactive compounds or thermally unstable compounds or mixtures. Dottikon uses its technology and equipment to design, develop and optimize chemical processes, and scale up from kilograms to multi-tons. It also offers high-purity isosorbide dimethyl ether, which finds application in cosmetics, pharmaceutical, chemical and agricultural industries. It provides recycling and waste management services including recycling of solvents, high-temperature incineration, thermal recovery, and waste water treatment and purification. The company operates through Dottikon ES Group and has subsidiaries in Switzerland and the US. Dottikon is headquartered in Dottikon, Aargau, Switzerland.Dottikon ES Holding AG Key Recent DevelopmentsJul 01, 2016: DOTTIKON ES' Shareholders Approve all Proposals of the Board of DirectorsMay 31, 2016: DOTTIKON ES Tenfold Increase in Net Income in Business Year 2015/16Apr 15, 2016: DOTTIKON ES Strong Organic Sales Growth in Business Year 2015/16Mar 11, 2016: DOTTIKON ES Major Investments and Increase in Headcount in SwitzerlandNov 27, 2015: DOTTIKON ES Further Increase in Net Sales and Net IncomeKey benefits of buying this profile include:You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.Gain key insights into the company for academic or business research.- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.Note: Some sections may be missing if data is unavailable for the company
Table of ContentsTable of Contents 2List of Tables 4List of Figures 5Section 1 - About the Company 6Dottikon ES Holding AG - Key Facts 6Dottikon ES Holding AG - Key Employees 7Dottikon ES Holding AG - Key Employee Biographies 8Dottikon ES Holding AG - Major Products and Services 9Dottikon ES Holding AG - History 10Dottikon ES Holding AG - Company Statement 11Dottikon ES Holding AG - Locations And Subsidiaries 12Head Office 12Other Locations & Subsidiaries 12Affiliate 12Section 2 Company Analysis 13Dottikon ES Holding AG - Business Description 13Dottikon ES Holding AG - Corporate Strategy 15Dottikon ES Holding AG - SWOT Analysis 16SWOT Analysis - Overview 16Dottikon ES Holding AG - Strengths 16Strength - Business Performance: Pharmaceutical Products 16Strength - Research and Development (R&D) Capabilities 16Strength - Technology Portfolio 16Strength - Organic Growth 16Dottikon ES Holding AG - Weaknesses 18Weakness - Operations: Performance Chemicals 18Weakness - Dependence on Few Customers 18Dottikon ES Holding AG - Opportunities 19Opportunity - Market Outlook: Active Pharmaceutical Ingridients (APIs) 19Opportunity - Changing Demographics 19Opportunity - Strategic Initiatives 19Dottikon ES Holding AG - Threats 20Threat - Foreign Exchange Fluctuations 20Threat - Intense Competition 20Threat - Stringent Regulations 20Dottikon ES Holding AG - Key Competitors 21Section 3 Company Financial Ratios 22Financial Ratios - Capital Market Ratios 22Financial Ratios - Annual Ratios 23Performance Chart 25Financial Performance 25Financial Ratios - Interim Ratios 26Financial Ratios - Ratio Charts 27Section 4 Company's Lifesciences Financial Deals and Alliances 28Dottikon ES Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 28Dottikon ES Holding AG, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 29Dottikon ES Holding AG, Recent Deals Summary 30Section 5 Company's Recent Developments 31Jul 01, 2016: DOTTIKON ES' Shareholders Approve all Proposals of the Board of Directors 31May 31, 2016: DOTTIKON ES Tenfold Increase in Net Income in Business Year 2015/16 32Apr 15, 2016: DOTTIKON ES Strong Organic Sales Growth in Business Year 2015/16 34Mar 11, 2016: DOTTIKON ES Major Investments and Increase in Headcount in Switzerland 35Nov 27, 2015: DOTTIKON ES Further Increase in Net Sales and Net Income 36Jul 03, 2015: DOTTIKON ES' Shareholders Approve all Proposals of the Board of Directors 39May 29, 2015: DOTTIKON ES Higher Sales and Net Income 40Section 6 Appendix 42Methodology 42Ratio Definitions 42About GlobalData 46Contact Us 46Disclaimer 46List of TablesDottikon ES Holding AG, Key Facts 6Dottikon ES Holding AG, Key Employees 7Dottikon ES Holding AG, Key Employee Biographies 8Dottikon ES Holding AG, Major Products and Services 9Dottikon ES Holding AG, History 10Dottikon ES Holding AG, Subsidiaries 12Dottikon ES Holding AG, Affiliate 12Dottikon ES Holding AG, Key Competitors 21Dottikon ES Holding AG, Ratios based on current share price 22Dottikon ES Holding AG, Annual Ratios 23Dottikon ES Holding AG, Interim Ratios 26Dottikon ES Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 28Dottikon ES Holding AG, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016 29Dottikon ES Holding AG, Recent Deals Summary 30Currency Codes 42Capital Market Ratios 42Equity Ratios 43Profitability Ratios 43Cost Ratios 44Liquidity Ratios 44Leverage Ratios 45Efficiency Ratios 45List of FiguresDottikon ES Holding AG, Performance Chart (2012 - 2016) 25Dottikon ES Holding AG, Ratio Charts 27Dottikon ES Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 28Dottikon ES Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 29